Structure Therapeutics (GPCR) Expected to Announce Earnings on Thursday

Structure Therapeutics (NASDAQ:GPCR) will likely be issuing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

Structure Therapeutics Stock Performance

Structure Therapeutics stock opened at $68.91 on Wednesday. Structure Therapeutics has a twelve month low of $13.22 and a twelve month high of $94.90. The firm has a market cap of $4.87 billion, a PE ratio of -56.48 and a beta of -2.06. The firm’s 50 day moving average price is $75.27 and its two-hundred day moving average price is $45.95.

Analyst Ratings Changes

A number of research firms have recently weighed in on GPCR. BMO Capital Markets reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research note on Tuesday, January 6th. JPMorgan Chase & Co. boosted their target price on Structure Therapeutics from $65.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, January 22nd. Piper Sandler reaffirmed an “overweight” rating on shares of Structure Therapeutics in a research note on Tuesday, October 28th. Morgan Stanley lifted their price target on Structure Therapeutics from $120.00 to $125.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Finally, The Goldman Sachs Group raised Structure Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 20th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Structure Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $106.20.

Institutional Trading of Structure Therapeutics

Several large investors have recently made changes to their positions in the stock. State of Wyoming bought a new position in shares of Structure Therapeutics in the 2nd quarter valued at approximately $28,000. Police & Firemen s Retirement System of New Jersey bought a new stake in Structure Therapeutics during the fourth quarter worth approximately $127,000. Raymond James Financial Inc. acquired a new position in Structure Therapeutics during the second quarter valued at approximately $129,000. Cibc World Market Inc. bought a new position in shares of Structure Therapeutics in the fourth quarter valued at approximately $226,000. Finally, Engineers Gate Manager LP bought a new position in shares of Structure Therapeutics in the second quarter valued at approximately $329,000. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.